INTRODUCTION {#S1}
============

The hematopoietic lineage emerges during a narrow developmental window from a specialized subset of endothelial cells: the hemogenic endothelium (HemEnd) ([@R23]). Hematopoietic stem progenitor cells (HSPCs) enter the circulation from HemEnd sites to first seed and expand the fetal liver and later occupy the bone marrow.

The specification of the HemEnd requires *Etv2* and *Runx1*, while HSPCs budding from the HemEnd involves *Gata2*, *Jagged1-Notch*, and *Hedgehog* ([@R15]; [@R24]). In recent years, the field has come to appreciate the diversity, repopulation capacity, and plasticity of single hematopoietic stem cells (HSCs) at the HemEnd stage, meaning before their seeding in hematopoietic organs ([@R27]). For example, VE-Cadherin-expressing HemEnd gives rise to myeloid-erythroid biased HSPCs ([@R14]), while TGF-β and BMP signaling differentially activate myeloid versus lymphoid-biased HSCs ([@R12]; [@R17]). It is well known that lineage-specific transcription factors that drive specification of blood cells (CEBPa, Ikaros, MLL, SCL, Etv6, etc.) can lead to leukemia when deregulated ([@R38]). Similarly, genes involved in the regulatory process that control budding of HSCs from the HemEnd might also promote neoplastic transformation when disrupted.

Seeking to expand our current understanding of the genes that regulate hematopoiesis (and their potential transformation) starting as early as HSPC budding, we performed a forward genetic screen using *Sleeping Beauty* (SB) transposon mutagenesis to target the HemEnd. On insertion into the genome, transposons disrupt splicing and expression of targeted genes, causing both gain- and loss-of-function events and facilitating the discovery of oncogenes and tumor suppressors in a variety of solid and blood cancers ([@R36]). HemEnd-initiated SB transposon mutagenesis yielded myeloid, erythroid, and lymphoid malignancies with mutations in both well-known regulators of those lineages and candidate genes uncovered in this study. Among these candidates, we identified a previously unknown role for phosphatidyl inositol lipid kinase (Pi4ka) in erythroid and myelopoiesis. Recurrent *Pi4ka* mutations were previously identified in histiocytic sarcomas driven by SB mutagenesis in cells expressing a myeloid-specific Lyz-Cre transgene, but no causative mechanisms were reported ([@R5]). A lipid kinase that phosphorylates phosphatidyl-inositols at the D4 position, the Pi4ka protein may be important in a broad array of biological processes, including signaling complexes, ion channel activity, lipid transfer, vesicle transport, and actin binding ([@R3]; [@R35]). Here, we validated Pi4ka's biological significance in hematopoiesis and demonstrated its link to Akt and Erk signaling, the former classically known to regulate hematopoietic differentiation. Furthermore, we identified the human PI4KA "pseudogene," PI4KAP2, as a dominant-negative inhibitor of the PI4KA signaling pathway.

RESULTS {#S2}
=======

HemEnd Mutagenesis Promotes Hematopoietic Malignancies {#S3}
------------------------------------------------------

We targeted mutagenesis to the endothelium using a conditional SB transposon strategy ([@R21]) ([Figures 1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}). VE-Cadherin-Cre (VEC-Cre) recombinase ([@R1]) was used to drive expression of the transposase enzyme specifically in endothelial cells, where it could cut and paste transposons randomly into TA dinucleotides distributed throughout the genome ([@R40]). VEC-Cre is first expressed in the HemEnd by embryonic day (E) 9.5 in a salt-and-pepper manner with progressive penetration and homogeneous expression by E12.5 ([@R1]). Due to this mosaic expression pattern in the HemEnd (transient phase lasting from E10.5--E12.5) by E10.5, some cells were targeted by mutagenesis while others were not, creating a competitive mixture of mutated and non-mutated populations.

Whereas a previous SB screen targeting HSCs using Vav-Cre ([@R6]) yielded only lymphoid leukemia, the VEC-Cre screen generated both myeloid and lymphoid malignancies. A total of 76 Cre^+^ and 15 Cre^−^ (non-mutagenized) mice were evaluated, with 59 Cre^+^ and 0 Cre^−^ mice presenting with pathology. From this cohort, 55.3% (n = 42) developed hematopoietic abnormalities alone, 9.2% (n = 7) developed vascular anomalies, and 13.2% (n = 10) developed a combination of both ([Figure 1Ci](#F1){ref-type="fig"}). Mice with hematopoietic abnormalities were further categorized into those with an enlarged spleen (65.4%, n = 34), an enlarged thymus (13.5%, n = 7), or both (21.2%, n = 11) ([Figure 1Cii](#F1){ref-type="fig"}). Overall, mutagenized mice had a mean survival of 179 days ([Figure 1D](#F1){ref-type="fig"}). An enlarged thymus was associated with faster disease kinetics compared with splenomegaly (mean survival of 139 days versus 161 days, respectively) ([Figure 1E](#F1){ref-type="fig"}). Representative images of pathology are shown in [Figure 1F](#F1){ref-type="fig"}. Affected mice had \~4- to 7-fold increased white blood cell counts compared with Cre^−^ littermates ([Figure 1G](#F1){ref-type="fig"}) and frequently exhibited anemia (reduced red blood cell \[RBC\] count and hemoglobin \[Hg\] concentration) and increased RBC size (mean corpuscular volume \[MCV\]) ([Figure 1H](#F1){ref-type="fig"}). Although affected mice commonly had abnormal platelet counts compared with Cre^−^ animals, no differences were observed based on the primary affected site ([Figure 1I](#F1){ref-type="fig"}). Overall, the findings indicate that targeted mutagenesis initiated in the HemEnd results in hematopoietic malignancies.

Spleen and Thymus Malignancies Have Distinct Mutation Signatures {#S4}
----------------------------------------------------------------

The SB mutagenesis system enables precise genomic coordinates of transposon-induced mutations to be determined using linker-mediated PCR and Illumina next-generation sequencing ([@R9]). Subsequent statistical analyses identified recurrently mutated regions containing clonally expanded transposon insertions at a higher rate than would be predicted in the absence of selective pressure. Because these analyses assumed a random transposition pattern, we first confirmed the unbiased distribution of insertions across all chromosomes in affected spleen and thymus DNA samples ([Figures S1A--S1C](#SD1){ref-type="supplementary-material"}). Indeed, our data were consistent with the well-established unbiased nature of SB screens in general ([@R4]; [@R21]; [@R29]; [@R40]). We next used gene-centric common insertion site (gCIS) analysis to identify clusters of clonally expanded insertions enriched near protein coding regions. Interestingly, the number of gCISs associated with the thymus phenotype was double that of the spleen phenotype, despite the same average number of total insertions per sample ([Figures S1D and S1E](#SD1){ref-type="supplementary-material"}), supporting the concept that the cell of origin influences gCIS mutations, which in turn influences malignancy ([@R6]).

Our screen activated transposon-mediated mutagenesis in the HemEnd and thus early definitive HSCs. A comparison of the gCIS list with recurrently mutated genes identified in blood cancers arising from global (non-tissue specific) and Vav-Cre-(HSPC)-driven mouse mutagenesis screens revealed substantial overlap, highlighting the ability of this approach to identify genes relevant to lymphoid malignancies ([Figure 2A](#F2){ref-type="fig"}; [Tables S1 and S2; Figure S1F](#SD1){ref-type="supplementary-material"}). Of note, previous HSPC-targeting screens were not also able to generate myeloid malignancies without mutant JAK sensitization.

The most commonly mutated genes for the enlarged thymus phenotype were *Rasgrp1*, *Akt1*, and *Akt2*, with insertions often occurring concurrently in the same lesion ([Figures 2B](#F2){ref-type="fig"} and [2C](#F2){ref-type="fig"}). Additional frequently mutated genes included *Notch1* and *Myc* ([Figure 2B](#F2){ref-type="fig"}). Many of the genes identified in this cohort have been previously associated with T cell malignancy ([@R33]; [@R37]; [@R39]).

Frequently mutated genes in enlarged spleens were *Eras*, *Erg*, and *Ets1*, which occurred in 40% of samples ([Figures 2D](#F2){ref-type="fig"} and [2E](#F2){ref-type="fig"}). Other recurrently mutated genes included *Fli1*, *Epo*, and *Runx2* ([Figure 2E](#F2){ref-type="fig"}). Interestingly, several genes were commonly found together in a single spleen, suggestive of a cooperative function in transformation, and included: *Eras, Erg*, and *Epo*; *Erg* and *Ets1*; and *Fli1* and *Runx2* ([Figure 2F](#F2){ref-type="fig"}). These genes have been implicated in pathological myelo-erythropoiesis and hematopoiesis in general, providing strong validation to the screen ([@R2]; [@R28]; [@R48]). Interestingly, malignancies resulting from HemEnd-initiated mutagenesis frequently contained mutations in genes like *Pi4ka*, *Erg*, and *Fli1*, which are more highly expressed in HSCs compared with other hematopoietic progenitor cells ([Figures 2G](#F2){ref-type="fig"}--[2I](#F2){ref-type="fig"}) ([@R11]). Most splenomegaly associated mutations were also correlated with abnormal blast-like cells in the blood and reduction in polymorphonuclear cells in the bone marrow ([Figures S2A and S2B](#SD1){ref-type="supplementary-material"}).

Pi4ka Insertion Is Associated with Progenitor Accumulation and Reduced RBCs {#S5}
---------------------------------------------------------------------------

We next focused on *Pi4ka*, which, unlike most of the genes identified by the screen, had not been previously associated with hematopoietic abnormalities or hematopoiesis in general. The three *Pi4ka* transposon insertions (each from a distinct individual) were distributed throughout the gene in both transcriptional orientations ([Figure 3A](#F3){ref-type="fig"}), a pattern suggestive of inactivating mutations ([@R16]). Consistent with this hypothesis, the mutations were associated with decreased *Pi4ka* mRNA ([Figures 3B](#F3){ref-type="fig"} and [3C](#F3){ref-type="fig"}), and immunohistochemical analyses indicated a significant decrease of Pi4ka protein compared with controls ([Figure 3D](#F3){ref-type="fig"}). Histological evaluation of affected spleens also revealed expanded red pulp zones compared with Cre^−^ spleens ([Figure 3D](#F3){ref-type="fig"}). May-Grunwald stain of white blood cells from mice with *Pi4ka* insertions showed a prevalence of myeloid lineage, nucleated erythroid lineage, and blast-like immature cells ([Figure 3D](#F3){ref-type="fig"}, bottom). Strikingly, when the *Pi4ka* insertion occurred in the absence of additional gCIS mutations (F270), the predominant cell type was blast-like and immature, which was also associated with anemia ([Figures 3D](#F3){ref-type="fig"} \[bottom\] and 3E). On the other hand, when the *Pi4ka* mutation occurred in the same lesion as either the *Epo* or *Fli1* mutation, lesions appeared myelodysplastic and were characterized by an abundance of nucleated erythroid lineage cells ([Figure 3D](#F3){ref-type="fig"}, bottom).

Pi4ka Insertions Are Associated with Impaired Myelo- and Erythropoiesis {#S6}
-----------------------------------------------------------------------

To assess the cellular composition and clonality of spleens with *Pi4ka* mutations, we first performed transcriptome analysis of both mutant and control spleens ([Figure 4A](#F4){ref-type="fig"}). Based on the expression of cell-type-specific markers ([@R47]), *Pi4ka* mutant spleens had less lymphocytic, more HSCs, and more common myeloid progenitor (CMP) features when compared with controls. Animal F270 had the least mature monocyte-macrophage character, both F270 and F262 had increased granulocyte-monocyte progenitor (GMP) features, and both F270 and M267 had decreased mature erythroid hemoglobin transcripts. These results led us to hypothesize that Pi4ka might have a role in erythroid and myeloid maturation. Consistently, downregulated genes were enriched for Gene Ontology categories related to mature blood cells markers ([Figure 4B](#F4){ref-type="fig"}), and upregulated genes were enriched for categories related to cell proliferation ([Figure 4C](#F4){ref-type="fig"}). Expression of the genes defined in [Figure 4A](#F4){ref-type="fig"} revealed strong similarity between two independent regions of each affected and control spleen (Pearson correlation; diagonal) ([Figure 4D](#F4){ref-type="fig"}), indicating that the anomalies were clonal. As anticipated, comparisons between individuals showed much lower correlation.

Pi4ka Is Expressed in HSPC Budding from the HemEnd and in Adult Mouse Lineage-Negative Bone Marrow Cells {#S7}
--------------------------------------------------------------------------------------------------------

Next, we sought to evaluate the expression profile of Pi4ka in the hematopoietic compartment. Immunofluorescence staining in E9.5 mouse aortas captured HSPC, budding from HemEnd (CD31^+^), expressing Pi4ka at the cell membrane ([Figure S3A](#SD1){ref-type="supplementary-material"}). Pi4ka was also expressed in a subset of CD45^+^, lineage-cocktail-negative cells in the mouse adult bone marrow, but not in the associated vasculature (Cdh5^+^) ([Figures S3B and S3C](#SD1){ref-type="supplementary-material"}). To confirm these findings, we performed qPCR for *Pi4ka* on sorted adult bone marrow cell populations, detecting elevated expression in Lin Sca1^+^cKit^+^ HSPCs compared with other progenitor populations and the Lin^+^ cell fraction ([Figure S3D](#SD1){ref-type="supplementary-material"}). In addition, a microarray data from BloodChIP ([@R11]) demonstrates the highest *PI4KA* expression in human HSC, multipotential progenitor (MPP), and megakarycocyte/erythrocyte progenitor (MEP) populations in addition to acute myeloid leukemia (AML) ([Figure S3E](#SD1){ref-type="supplementary-material"}).

Loss of *pi4kaa* Function in Zebrafish Inhibits Erythroid Differentiation {#S8}
-------------------------------------------------------------------------

To further explore the biological relevance of Pi4ka in an independent system, we evaluated the role of zebrafish homolog *pi4kaa* in hematopoiesis. A splice inhibitory morpholino targeting the catalytic domain prevented splicing of *pi4kaa* exons 49 and 50 in a dose-dependent manner ([Figure S4A](#SD1){ref-type="supplementary-material"}). *o*-Dianisidine staining indicated lower hemoglobin content in the 48 hr post-fertilization (hpf) morphant embryos compared with controls ([Figure S4B](#SD1){ref-type="supplementary-material"}). To quantify differences in erythroid lineage cells, flow cytometry was performed on control and morpholino-treated *gata1*:DsRED (erythroid cells); *fli1*:GFP (endothelial and hematopoietic progenitor cells); or *lcr*:GFP (erythroid cells) embryos (≥100 embryos per biological replicate) at 48 hpf. Morphant (MO) animals were treated with an additional p53 morpholino to enhance embryo viability, whereas control (C) animals were treated with just the p53 morpholino. Due to its long half-life, DsRED measurement was equivalent to total erythroid lineage cells. *Pi4kaa* inhibition resulted in significantly less erythroid lineage cells in both fish lines ([Figures 5A](#F5){ref-type="fig"} and [5B](#F5){ref-type="fig"}). *fli1*:GFP; *gata1*:DsRED fish were then used to assess the differentiation of erythroid line age cells in MOs. In C embryos, a prominent *fli1:GFP;gata1:*DsRED double-positive population was observed at 24 hpf, characteristic of immature hematopoietic cells ([Figure S4C](#SD1){ref-type="supplementary-material"}). As development proceeded and cells differentiated, this population was decreased. By 48 hpf, *gata1*:DsRED cells had lost *fli1*:GFP expression in C embryos ([Figure S4D](#SD1){ref-type="supplementary-material"}). In contrast, the *fli1*:GFP;*gata1*:DsRED double-positive population was partially retained in *pi4kaa* MOs (\~3.5 higher median *fli1*:GFP expression) ([Figure 5C](#F5){ref-type="fig"}; [Figure S4E](#SD1){ref-type="supplementary-material"}).

We performed qPCR on whole *pi4kaa* MO and C embryos to assess markers of stem and mature blood cells. Indicators of hematopoiesis *gata1* (erythroid progenitor marker), *lmo2* (erythroid-myeloid progenitor marker), and *pu.1* (myeloid progenitor marker) were higher in MOs at 24 hpf ([Figure 5D](#F5){ref-type="fig"}). While *beta-globin* was slightly lower than in Cs, the mature myeloid markers *mpx* and *l-plastin* were not affected in *pi4kaa* MOs ([Figure 5E](#F5){ref-type="fig"}).

*Pi4ka* Knockdown in Mouse HSPC Impairs Progression of Mouse Erythro- and Myelopoiesis *In Vitro* in a Cell-Autonomous Manner {#S9}
-----------------------------------------------------------------------------------------------------------------------------

Given the evidence for a role in zebrafish erythropoiesis, we sought to determine the importance of Pi4ka in murine myelo- and erythropoiesis by evaluating HSPC differentiation *in vitro*. As the zebrafish experiments involved "whole-body" *pi4kaa* targeting, we sought to test whether Pi4ka loss functioned in a hematopoietic-cell-autonomous manner. We sorted adult mouse bone marrow HSPCs (Lin^−^ cKit^+^Sca1^+^), treated with either lentivirus (lenti)-small hairpin RNA against *Pi4ka* or scrambled sequence for 24 hr, washed to remove virus, and subsequently co-cultured on an OP9 stromal layer in the presence of cytokines ([Figure 5F](#F5){ref-type="fig"}). After 10 days of culture, flow cytometry revealed significantly less CD71^−^ (immature erythroid marker), Ter119^+^ (mature eythroid marker) erythroid linage cells in cultures derived from shRNA for Pi4ka (shPi4ka)-treated HSPCs ([Figures 5G](#F5){ref-type="fig"} and [5H](#F5){ref-type="fig"}). Similarly, an increase in Mac1^+^ (Mac1 high), F4/80^+^ (F4/80 high) cells with a complementary decrease in Mac1^−^ (Mac1 low), F4/80^+^ (F4/80 high) cells was observed in the shPi4ka-treated condition ([Figures 5I](#F5){ref-type="fig"} and [5J](#F5){ref-type="fig"}), reflecting the phenotype seen in mouse F270 from the original screen. A differentiation assay in the G1E-ER4 cell line also demonstrated an arrest in progressive differentiation (Ter119 level) with shPi4ka treatment ([Figure S4F](#SD1){ref-type="supplementary-material"}).

Akt and Erk Signaling Is Altered Downstream of Pik4a Knockdown In Vitro {#S10}
-----------------------------------------------------------------------

To gain mechanistic clarity on pathways regulated downstream of Pi4ka, we explored the effect of loss of function on a panel of relevant signaling effectors. Pi4ka knockdown by lentiviral shRNA in 32D mouse myeloid lineage cells ([Figure 6A](#F6){ref-type="fig"}, right) significantly increased phospho-ERK (p-Erk) and depressed interleukin-3 (IL-3)-induced p-Akt, as determined by western blot and flow cytometry ([Figure 6A](#F6){ref-type="fig"}; [Figure S5A](#SD1){ref-type="supplementary-material"}). We validated the signaling effects in another cell type (HEK293), where *Pi4ka* small interfering RNA (siRNA) enhanced stem cell factor (SCF)-induced p-Erk levels ([Figure 6B](#F6){ref-type="fig"}). Together, these results suggest that Pi4ka is important for regulating the balance between p-Akt and p-Erk signaling downstream of the cytokine receptors interleukin-3 receptor (IL-3R) and cKit.

Human PI4KAP2 Protein Lacks Kinase Activity and It Is Upregulated in Myelo- and Erythroleukemia Cell Lines {#S11}
----------------------------------------------------------------------------------------------------------

According to the COSMIC genome database, *PI4KA* mutations have been found in 363 unique human cancer samples, including somatic frameshift mutation p.T1995fs\*4 in three lymphoid neoplasms (COSMIC Study COSU440) and many missense mutations, some occurring in primary and cell line leukemia. Interestingly, the human genome encodes pseudogenes, absent in mice, that could further affect PI4KA function. We hypothesized that human *PI4KAP2* (PI4KA pseudogene 2), which encodes an N-terminally truncated, kinase-domain-deleted version of the PI4KA protein ([Figures 7A](#F7){ref-type="fig"} and [7B](#F7){ref-type="fig"}), could act in a dominant-negative manner. The BloodChIP database indicates that the *PI4KA* promoter is similarly primed by activation marks in both CD34^+^ HSPCs and K562 eythroleukemia cells ([Figure S6A](#SD1){ref-type="supplementary-material"}), while the predicted *PI4KAP2* promoter has relatively higher activation marks in K562 ([Figure S6B](#SD1){ref-type="supplementary-material"}). Furthermore, K562 cells have both *PI4KA* and *PI4KAP2* promoter binding by the hematopoietic transcription factor Erg, while normal CD34^+^ HSPCs do not ([Figures S6C and S6D](#SD1){ref-type="supplementary-material"}).

Given the apparent increased *PI4KAP2* promoter accessibility/priming and concomitant hematopoietic transcription factor binding in malignant cells, we assessed differential expression in myeloid leukemia, lymphoid leukemia, normal hematopoietic progenitor cells, and normal blood mononuclear cells (monocytes and lymphocytes) ([Figure 7C](#F7){ref-type="fig"}). We designed primers to distinguish the *PI4KA* transcript (located in the region deleted in *PI4KAP2*) from the *PI4KAP1* and *PI4KAP2* transcripts (reverse primer spanning the region flanking the deleted kinase domain in *PI4KAP1/2*), although we were unable to distinguish between the two pseudogene transcripts. While *PI4KAP1/2* and *PI4KA* were similarly expressed in CD34^+^ cord blood cells, peripheral blood mononuclear cells (PBMCs), and a T cell leukemia cell line, the ratio of *PI4KAP1/2* to *PI4KA* expression was generally increased in myelo- and erythroleukemia cell lines, consistent with the BloodChIP data. We confirmed expression of PI4KAP2 protein in the myelo- and erythroleukemia cell lines using an antibody validated through decreased signal after siRNA knockdown in HEK293 cells ([Figure 7D](#F7){ref-type="fig"}). These results demonstrate that *PI4KAP2* codes for an expressed protein and is not a pseudogene, a conclusion further validated by fusing the cDNA sequence to a C-terminal hemagglutinin (HA)-tag. Both the exogenously expressed (HA-tagged) and endogenous protein were detected by western blot with a PI4KAP2 antibody ([Figure S7A](#SD1){ref-type="supplementary-material"}).

Given the lack of the kinase domain in PI4KAP2, we explored its potential role as an antagonistic regulator of PI4KA. As expected, PI4KAP2 protein purified from HEK293 cells using immuno-precipitation of the HA-tag displayed no *in vitro* kinase activity, in contrast to purified PI4KA protein ([Figure S7B](#SD1){ref-type="supplementary-material"}). We compared the impact of PI4KAP2 gain of function to PI4KA loss of function by probing an antibody microarray with lysates from HEK293 cells transfected with PI4KAP2 expression vector, C vector, siRNA against PI4KA, or C siRNA ([Figures S7C and S7D](#SD1){ref-type="supplementary-material"}). Protein categories affected by altering PI4KA signaling included cytoskeleton regulation, Src-family kinases, MAPK family, NFkappaB, receptor tyrosine kinases, cell cycle regulators, JAK-STAT signaling members, intracellular kinases, adaptors, and lipases ([Figure 7E](#F7){ref-type="fig"}). Although there were some differences in the effects of PI4KAP2 expression and PI4KA knockdown, commonly affected proteins included: LIMK1 FYN, KIT, p38d MAPK, and STAT5A. The entire array can be found in [Table S3](#SD1){ref-type="supplementary-material"}.

DISCUSSION {#S12}
==========

Our results are consistent with literature reporting a pleiotropic requirement for Pi4ka in normal morphogenesis. In zebrafish, *pi4kaa* was shown to be necessary for pectoral fin development downstream of fibroblast growth factor receptor (FGFR) signaling through regulation of PI3K-Akt signaling ([@R32]). In *Drosophila*, it was shown to be required for smoothened activation during imaginal wing disc development ([@R46]). Furthermore, global deletion of *Pi4ka* in adult mice uncovered its requirement for gastrointestinal stability ([@R8]; [@R44]). Our data add to this body of knowledge and implicate *Pi4ka* in hematopoiesis.

We postulate that *Pi4ka* is likely to regulate hematopoiesis in several ways in addition to its effect in Akt signaling. Pi4ka is a lipid kinase that phosphorylates the D4 position of the phosphatidyl-inositol ring ([@R35]). The resulting phosphatidyl-inositol, 4-phosphate (PIP4) provides a docking point for other proteins to bind to the inner leaflet of the plasma membrane ([@R3]). Once docked, additional lipid kinases can phosphorylate the ring at other positions, creating more complex phosphatidyl-inositols that can become substrates for phospholipases. Interestingly, phospholipase gamma 1 has been shown to have a role in primitive zebrafish hematopoiesis ([@R31]). In fact, we observe defects of the primitive erythroid lineage when we inhibit *pi4kaa* in our zebrafish model. Furthermore, oxysterol-binding proteins, which insert sterols into the plasma membrane ([@R45]), require PIP4 to dock. Oxysterols themselves can inhibit the proliferation of hematopoietic cell progenitors ([@R26]). Plasma membrane fluidity, as well as the specific constituency of lipids, influences cell-surface receptor signaling ([@R42]). Indeed, sterols have been shown to affect smoothened activation and hedgehog signaling, which are known to regulate HemEnd - HSCs ([@R18]). Finally, there are early reports correlating changes in phosphatidyl-inositol lipid composition and hematopoietic cell proliferation and differentiation ([@R34]).

*PI4KAP2*, previously thought to not encode a functional protein, is the result of gene duplication in humans and does not exist in mice ([@R43]). However, we demonstrated that this gene is not only transcribed, but also translated into a protein that has signaling consequences. Based on its lack of a kinase domain, we hypothesized that the PI4KAP2 protein could act in a dominant-negative fashion (similar to the effects of losing expression of PI4KA). The ratio of PI4KAP2 to PI4KA is higher in myeloid and erythroid cell lines compared with other cell types tested. Strikingly, the ERG transcription factor was documented to bind to the promoter region, specifically in malignant (K562) cells. One could speculate of a scenario in which higher levels of ERG (such as in Down syndrome) could enhance PI4KAP2 expression and deregulate the PI4KA pathway in the context of in utero leukemia development. Our findings indicate that PI4KAP2 overexpression or PI4KA knockdown induces similar alterations in MAPK, Srk-family kinases, and JAK-STAT signaling pathways. We also documented the effect of PI4KAP2 and PI4KA on proteins like FAK, PAK1, STAT5, and KIT, which are known leukemia drivers ([@R13]). In addition, pi4kaa is known to regulate the PI3K-AKT pathway downstream of FGFR signaling ([@R32]). Our findings demonstrate similar effects in mouse 32D myeloid progenitor cells. FGFR1 signaling appears to be required for HSC repopulation, and increased expression of FGFR3 has been reported in CD34^+^ myeloid leukemia cells ([@R19]; [@R22]). In this study, PI4KAP2 overexpression altered FGFR3 protein levels as per findings in the antibody array.

In conclusion, this forward genetic screen supports the concept that mutations initiated at the hemogenic endothelium stage can carry consequences for the hematopoietic lineage. We identified Pi4ka as an important cell-autonomous regulator of hematopoiesis, which in turn pointed to PI4KAP2, found to be dysregulated in human myeloid and erythroid leukemia cell lines.

EXPERIMENTAL PROCEDURES {#S13}
=======================

Mice {#S14}
----

VEC-Cre; ROSA26-LacZ transgenic mice ([@R1]) were crossed to conditional ROSA26-LsL-SB transposase T2/Onc2 mice ([@R20]) to initiate mutagenesis in hemogenic endothelial cells starting at E9.5. VEC-Cre-negative and wild-type C57BL/6J mice were used as controls. iCdh5-Cre recombinase; Rosa26-TdTomato mouse femurs and tibia were flushed to isolate marrow strands ([@R30]). Animal protocols were reviewed and approved by the University of California, Los Angeles (UCLA) Institutional Animal Care and use Committee (ARC\#2005-223-33G).

Sequencing of Transposon Insertion Sites and Identification of Gene-Centric Common Insertion Sites (gCISs) {#S15}
----------------------------------------------------------------------------------------------------------

Genomic DNA from tumors was analyzed by ligation-mediated PCR (LM-PCR) to identify transposon integration sites, as previously described ([@R6]). Briefly, genomic DNA was digested with either *Alu*I or *Nla*III restriction enzymes. Double-stranded adaptor oligonucleotides were ligated to free DNA ends, followed by two rounds of PCR with nested primers to specifically amplify transposon/genome junctions and add on sequences necessary for sequencing. Amplified junctions were purified and sequenced using Illumina HiSeq. Clonal insertion sites were defined and gene-centric CIS (gCIS) analyses were performed to identify candidate genes implicated in tumorigenesis, as previously described ([@R9]).

Hematology {#S16}
----------

Complete blood count (CBC) analysis was performed using a Hemavet machine (Drew Scientific). After RBC lysis, leukocytes were spun onto slides using a Shandon Cytospin 4 (Themo Fisher Scientific). Slides were stained with May-Grunwald and Giemsa stains (Sigma-Aldrich).

Immunohistochemistry {#S17}
--------------------

Paraformaldehyde-fixed, paraffin-embedded tissue sections were deparaffinized, subjected to heat-mediated antigen retrieval, blocked with normal serum, and stained with antibody against Pi4ka. Biotinylated anti-rabbit secondary antibody was followed by Avidin-Biotin Complex Elite and DAB Peroxidase Kit (Vector Laboratories). See antibodies in [Supplemental Experimental Procedures](#SD1){ref-type="supplementary-material"}. An Olympus DP73 camera and cellSens software were used to image non-fluorescent stains.

RNA Sequencing {#S18}
--------------

RNA was purified using an RNeasy mini kit (QIAGEN), and libraries were prepared with a TruSeq polyA selection kit using 1 mg of RNA manually or a TruSeq stranded polyadenylation (poly-A) selection kit with 50 ng of RNA using the NeoPrep system (Illumina). Libraries were sequenced on a HiSeq 4000 system (Illumina). For the clonal analysis, we sequenced single-end 50 bp. For the cell-subtype expression analysis, we sequenced paired-end 100 bp.

Fish {#S19}
----

Zebrafish lines were maintained in accordance with the UCLA Department of Laboratory Animal Medicine's Animal Research Committee guidelines. The following lines were used: Tg(gata1:DSRED; fli1:GFP), Tg(lcr:GFP) ([@R25]), and wild-type AB fish. lcr:GFP fish were purchased from the UCLA Zebrafish Core Facility. All embryos were treated with 1 × 1-phenul-2-thiorea (PTU) (to inhibit pigment formation) at 24 hpf. Eight pg or 12 pg of the splice-inhibitory *pi4kaa* morpholino was injected with 2 pg or 3 pg of p53 morpholino, respectively. Splicing efficiency was examined with previously published primers. See oligonucleotide sequences in [Supplemental Experimental Procedures](#SD1){ref-type="supplementary-material"}. *o*-Dianisidine stain was used to stain hemoglobin.

qPCR Transcriptional Analysis {#S20}
-----------------------------

RNA was isolated using RNeasy Mini and Micro kits (QIAGEN). Mouse tissue cDNA was made using a Superscript III system (Invitrogen). Zebrafish and human cDNA were generated with an iScript cDNA synthesis kit (BioRad). Twenty whole zebrafish per treatment were used for RNA isolation. Zebrafish, mouse, and human qPCR primers are listed in [Supplemental Experimental Procedures](#SD1){ref-type="supplementary-material"}. SYBR-Green-based qPCR (BioRad) was performed as previously described ([@R10]).

Cells {#S21}
-----

OP9 cells (a gift from the Mikkola Laboratory, UCLA) were cultured in alpha minimum essential medium (aMEM) with 2 mM L-glutamine, 1% pen-strep, 20% Hyclone (Thermo Fisher Scientific) fetal bovine serum (FBS). For OP9/leukocyte co-cultures, media was supplemented with 5 ng/mL thrombopoietin (TPO), 50 ng/mL SCF, 10 ng/mL FMS-like tyrosine kinase 3 ligand (Flt3L), 5 ng/mL interleukin-6 (IL-6), and 5 ng/mL IL-3 (Peprotech). 32D cells (CRL-11346 American Type Culture Collection \[ATCC\]) were cultured according to ATCC recommendations with 10 ng/mL IL-3. Lenti-X HEK293 cells (632180 Clonetech) were cultured in DMEM 10% FBS. G1E-ER4 cells (a gift from the Ganz Laboratory, UCLA) were cultured with tamoxifen according to [@R41]. BV173, KCL22, and K562 cells (a gift from the Colicelli Laboratory, UCLA), Tf1a (ATCC CRL-2451) and HEL 92.1.7 (ATCC TIB-180) were all cultured according to ATCC recommendations.

Human PBMC and CD34^+^ cord blood cells were purchased from the UCLA/Core Facility Research (CFAR) Virology Core Laboratory. Mononuclear cells were isolated using a Ficoll gradient. Monocytes (PBMC fraction adhering to a TC plate) and lymphocytes (non-adhered portion) were used for RNA. For cord blood, CD34^+^ (positive selected) and CD34^−^ (negative selected) blood cells were isolated using human Miltenyi MACS CD34 MicroBead Kit Ultra Pure and used for RNA.

Flow Cytometry and Cell Sorting {#S22}
-------------------------------

Flow cytometry was performed using BD Fortessa and LSRII machines (BD Biosciences). FACS was performed using BD Aria instruments. For RNA isolation of bone marrow subpopulations, Lin^+^, HSC (Lin^−^, cKit^+^, Sca1^+^, CD34^−^), GMP (Lin^−^, cKit^+^, Sca1^−^, CD34^−^, FcgR^+^), MEP (Lin^−^, cKit^+^, Sca1^−^, CD34^−^, FcgR^−^), and CMP (Lin^−^, cKit^+^, Sca1^−^, CD34^+^, FcgR^low^) cells were sorted from RBC-lysed bone marrow.

For OP9 cultures, HSC (Lin^−^, cKit^+^, Sca1^+^) cells were sorted after lineage depletion of bone marrow using mouse lineage depletion kit and LS columns (Miltenyi). Mouse hematopoietic cell differentiation on OP9 cultures was assessed from a single-cell suspension generated from cultured cells using antibodies against CD45, Mac1 (CD11b), F4/80, Ter119, and CD71.

Zebrafish flow cytometry and sorting was based on *fli1*:GFP, *lcr*:GFP or *gata1*:DsRED fluorescent signal (n = 100 per treatment). Dechorionated embryos were digested with 5 mg/mL Liberase-TM (Roche) for 1 hr at 33°C as in [@R7].

Molecular Cloning {#S23}
-----------------

The Pi4kap2 coding sequence was amplified from pDONR223-PI4KAP2 (23601 Addgene) using primers ([Supplemental Experimental Procedures](#SD1){ref-type="supplementary-material"}) that introduced an HA-tag at the 3′ end and flanked the fragment with PstI and *Age*I restriction enzyme sequences. The fragment was ligated into the pJet cloning vector using CloneJET kit instructions (K1231 Thermo Fisher Scientific) and amplified in Stbl3 bacteria (C737303 Thermo Fisher Scientific). The pLV-Ef1a-MCS-IRES-RFP-puro plasmid and the Pi4kap2HA-pJet vector were linearized with PstI and *Age*I. The Pi4kap2-HA fragment was gel purified and ligated into the pLV vector using T4 ligase. For the shRNA vector purchased from Origene (TL510615), the MND-GFP cassette (a gift from the Kohn Laboratory) was used to replace the CMV-GFP reporter.

Lenti shRNA Transduction {#S24}
------------------------

Pi4ka or scrambled shRNA plasmids along with VSG-G and ?8.2 packaging plasmids were transfected into 293T cells using Lipofectamine 2000 (Life Technologies). Virus was collected and concentrated by centrifugation. For primary HSPCs, high concentration virus was used to doubly infect cells using Retronectin-coated (Clontech) plates (40 μg/mL) after an overnight pre-stimulation in serum-free StemSPAN (StemCell Technologies, Inc.) or StemMACS (Miltenyi) supplemented with four times the cytokine concentration used in OP9 co-culture over the course of 24 hr before being washed and moved to OP9 stromal cells. For 32D and G1E-ER4 cells, the same virus was used to doubly infect cells using Retronectin-coated plates as above for 24 hr in the presence of culture medium.

Cell Transfection {#S25}
-----------------

For siRNA studies, HEK293 cells were treated with 60 pmol non-targeted (4390843 Invitrogen), Pi4ka-targeted siRNA (4392420 ID:s224264, Invitrogen) or Pi4kap2-targeted siRNA (4390771 ID: n310610) in the presence of Lipofectamine RNAi Max (Invitrogen) for two days. Similarly, for overexpression of Pi4kap2, cells were treated with 3 μg of pLV-Ef1a-Pi4kap2-HA-RFP in the presence of Lipofectamine2000 (Invitrogen) for two days.

Western Blot {#S26}
------------

32D cells and HEK293 cells were lysed in modified radioimmunoprecipitation assay (mRIPA) buffer (50 mM Tris, pH 7.4, 1% NP-40, 0.25% sodium deoxycholate, 1 mM EDTA, 0.15M NaCl, and 10mM beta-glycerophosphate) in the presence of 200 mM Na~3~VO~4~ and protease inhibitor cocktail (11873580001, Sigma). Lysates were run on 4%--20% gradient acrylamide gels (BioRad) and transferred to nitrocellulose membranes. See antibodies in [Supplemental Experimental Procedures](#SD1){ref-type="supplementary-material"}.

Antibody Array {#S27}
--------------

Cell lines expressing Ef1a-Pi4kap2-HA-RFP, Ef1a-RFP empty vector, non-targeted siRNA, or Pi4ka-targeted RNA were lysed in protein lysis buffer (5 mM EDTA, 2 mM EGTA, 20 mM 3-(N-morpholino)propanesulfonic acid (MOPS), pH 7.0, 20 mM NaF, 20 mM Na~4~P~2~0~7~, 1 mM Na~3~VO~4~, 60 mM beta-glycerophosphate, 50 nM phenylarsine oxide, 1% Triton X-100) containing protease inhibitor cocktail and phosphatase inhibitors. Samples were sonicated and then centrifuged for 30 min at 14,000 × *g*. Protein was quantified and pooled at equal concentrations. Lysates were then probed using the Kinexus KAM-900P array (Kinexus Bioinformatics Corporation), which contains 613 phospho-site-specific antibodies and 265 pan-specific antibodies (targeting 878 cell signaling proteins).

Statistical Analysis {#S28}
--------------------

For every dataset, it was first determined wither parametric or non-parametric analysis was appropriate and the use of either Student's t test or Mann Whitney to assess significance. Log-rank test was used for survival curve statistics. Paired Student's t test and one-way ANOVA were used to assess the significance of transcriptional differences between sorted hematopoietic sub-populations with the null assumption that they were the same. Paired Student's t test was used to assess significance between experimental and C conditions for zebrafish and OP9 co-culture experiments. Unpaired Student's t test was used for western blot and MFIR calculations. Statistical analyses were performed in Prism 7.0 according to the manufacturer's recommendations (GraphPad Software) (\*p ≤ 0.05; \*\*p ≤ 0.01; \*\*\*p ≤ 0.001; \*\*\*\*p ≤ 0.0001).

DATA AND SOFTWARE AVAILABILITY {#S29}
==============================

The accession number for all datasets reported in this paper is GEO: GSE108355.
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![Initiating Mutagenesis in the Hemogenic Endothelium Generates Hematopoietic Malignancies\
(A and B) Onset of VE-Cadherin-Cre (VEC-Cre) expression, and therefore SB Transposase, at E9.5 in the progeny of (B) SB T2/Onc2; VEC-Cre/Rosa26-LacZ mice.\
(C) Frequencies of abnormalities in these mice (i). Relative occurrence of enlarged spleens and thymus (ii).\
(D) Overall survival of Cre+ and CrE^−^ mice (number of mice in parentheses).\
(E) Kaplan-Meier curve breakdown of animals with indicated maladies.\
(F) Cre^+^ enlarged thymus (i), Cre^−^ normal thymus (ii), Cre^+^ enlarged spleen and Cre^−^ normal spleen (iii). Scale bar, 5 mm.\
(G) White blood cell counts for Cre^+^ animals with enlarged spleens (S; n = 24), enlarged thymus (T; n = 5), or a combination of both (S+T; n = 10), Cre^−^ littermates (n = 10).\
(H) Red blood cell (RBC) concentration, hemoglobin (Hb) concentration, and mean cell volume (MCV) for Cre^+^ animals with an enlarged spleen (S; n = 24), thymus (T; n = 5), or both (S+T; n = 10) compared with Cre^−^ controls (Cs; n = 10).\
(I) Platelet concentrations (PLT) and platelet distribution width (PDW%) in S, T, S+T, and C animals.\
(G--I) Data are represented as mean ± SEM, Student's t test (\*p ≤ 0.05; \*\*p ≤ 0.01; \*\*\*p ≤ 0.001; \*\*\*\*p ≤ 0.0001) S, enlarged spleen; T, enlarged thymus; C, Cre negative; VT, vascular tumors; NOA, no obvious abnormalities; Hem, hematopoietic malignancy; HSPC, hematopoietic stem progenitor cell; Hb, hemoglobin; MCV, mean corpuscular volume; PLT, platelet count; PDW%, size distribution of platelet width.](nihms941209f1){#F1}

![Thymus and Spleen Malignancies Have Distinct Gene Insertion Signatures\
(A) gCIS associated with thymic abnormalities in this screen when compared with others.\
(B) Most commonly mutated genes in enlarged thymus.\
(C) Distribution of mutated genes (rows) in each mouse (column). F, female; M, male. The number relates to the ID of the individual mouse. Enlarged thymus phenotype is shown in blue, enlarged spleen and thymus are depicted in green. Size of the thymus is shown at the bottom as a reference (3 \> 500 mg, 500 \> 2 \> 100 mg, 1 \< 100 mg).\
(D) gCIS associated with splenic abnormalities in this screen compared with other screens.\
(E) Most common gCISs in enlarged spleens.\
(F) Several genes (rows) were often found together in the same lesion (column).\
(G--I) mRNA expression as measured by microarray of myeloid-associated gCIS *Pi4ka* (G)*, Erg* (H), and *Fli1* (I) in different compartments from human bone marrow (BloodChIP); one-way ANOVA (\*p ≤ 0.05; \*\*p ≤ 0.01; \*\*\*p ≤ 0.001; \*\*\*\*p ≤ 0.0001). n = 4--8 per group.\
See also [Figures S1 and S2](#SD1){ref-type="supplementary-material"}.](nihms941209f2){#F2}

![Transposon Insertions in the Pi4ka Gene Are Associated with Blast-like Phenotype and Decreased Red Blood Cells\
(A) Transposon insertions throughout the *Pi4ka* gene.\
(B) *Pi4ka* RNA sequencing counts per million for affected and C spleens.\
(C) *Pi4ka* expression by qPCR of the individual spleens from affected mice compared to Cre^−^ spleens (n = 6).\
(D) H&E of Cre^−^ spleens and those with *Pi4ka* insertions (scale bar, 600 mm). Pi4ka immunohisto-chemistry (IHC) in spleens of C and affected mice (top: scale bar, 600 μm; middle: scale bar, 60 μm). Bottom: Cytospins of RBC-lysed blood from C and affected animals (scale bar, 15 μm)\
(E) CBC analysis in C and *Pi4ka*-affected animals. For Cs (Cre^−^), data are represented as mean ± SEM of n = 10 animals.](nihms941209f3){#F3}

![Molecular Characterization of Pi4ka Mutant Spleens\
(A) Hematopoietic gene transcriptional signatures for the three Pi4ka affected mice compared to three controls.\
(B and C) Gene Ontology categories enriched by genes downregulated (B) and upregulated (C) greater than 2-fold.\
(D) Clonal analysis comparing transcript counts for hematopoietic genes (as in A) between two regions of spleen removed from the same mouse (green boxes). Pearson correlations are color coded and visualized by circle size.\
See also [Figure S3](#SD1){ref-type="supplementary-material"}.](nihms941209f4){#F4}

![Loss of Pi4ka Decreases Erythroid Differentiation In Vivo and In Vitro\
(A) Percent of LCR-GFP cells in MO fish compared with C for three independent experiments. For each data point in (A)--(C), \>100 embryos were pooled and data are represented as mean ± SEM.\
(B) Percent Gata1-DsRED cells in MO fish compared with C for four independent experiments.\
(C) Graph of median Fli1:GFP intensity of the Gata1:DsRED parent population for four independent experiments.\
(D) RNA expression in 24 hpf whole C and morpholino-injected embryos for gata1, lmo2, pu.1, and scl transcripts for three to four independent experiments. For each data point in (D) and (E), 20 embryos were pooled and data are represented as mean ± SEM.\
(E) RNA expression in whole C and morpholino injected fish for b-globin, MPX, and l-plastin.\
(F) Illustration of *in vitro* mouse HSPC differentiation on an OP9 stromal layer for 10 days.\
(G) Three independent experiments in which shScrmb- and shPi4ka-infected HSPCs grown on OP9 stromal cells were probed for CD71 and Ter119 expression by flow cytometry.\
(H) Quantification of three independent experiments plotted as the fold difference of shScrmb and shPi4ka.\
(I) Mac1^+/−^ (Mac1 high/low) and F4/80^+/−^ (F4/80 high/low) expression and quantification in the same cells described in (G).\
(J) Quantification of four independent experiments.\
Bars indicate SEM. Student's t test and ANOVA were used to calculate significance between two groups (\*p ≤ 0.05; \*\*p ≤ 0.01; \*\*\*p ≤ 0.001; \*\*\*\*p ≤ 0.0001). See also [Figure S4](#SD1){ref-type="supplementary-material"}.](nihms941209f5){#F5}

![Loss of Pi4ka In Vitro Blunts Akt Signaling and Enhances ERK Signaling\
(A) Phospho-flow cytometry on 32D cells treated with 100 ng/mL IL-3 for 15 min. Fold change in MFI ratio of shPi4ka:shScrmb. Representative FACS plot (middle). Quantification of Pi4ka knockdown in 32D cells by qPCR (right) (summary of three independent experiments ± SEM).\
(B) HEK293 cells treated with siScrmb and siPi4ka were stimulated with 100 ng/mL SCF for 0, 5, and 10 min. Protein lysates were probed for Pi4ka, p-ERK, and gamma tubulin, as loading C. Quantification (right) (summary of three independent experiments ± SEM).\
Student's t test and ANOVA were used to compare two conditions with statistical significance defined as \*p ≤ 0.05; \*\*p ≤ 0.01; \*\*\*p ≤ 0.001; \*\*\*\*p ≤ 0.0001. See also [Figure S5](#SD1){ref-type="supplementary-material"}.](nihms941209f6){#F6}

![The Human PI4KAP2 Gene Yields a Protein Product and Has Higher mRNA Expression Relative to PI4KA in Erythro- and Myelo-Leukemia Cell Lines\
(A) Schematic comparing PI4KA and PI4KAP2 proteins. PI4KAP2 lacks the N-terminal domain and has a deletion in the kinase domain (red). PR, proline-rich domain; LKU, lipid kinase unique domain; PH, plekstrin homology domain.\
(B) Alignment of PI4KA and PI4KAP2 amino acid sequences shows major homology starting at amino acid 1,258 of PI4KA, except for missing amino acids in the kinase domain of PI4KAP2.\
(C) Ratio of mRNA expression of *PI4KAP2* and *PI4KAP1* compared with *PI4KA* in a panel of normal cord and peripheral blood cells (black), human lymphoid leukemia (blue), and myeloid leukemia (orange) cell lines.\
(D) Top: Validation of an antibody probing cells subjected to siRNA targeting PI4KAP2 and quantification. Bottom: Western blot showing endogenous PI4KAP2 in myeloid leukemia cell lines.\
(E) Antibody array summary of proteins that change when lysates from cells overexpressing PI4KAP2 were compared with vector C (left) and of proteins that change when lysates from cells knocked down for PI4KA were compared with C cells (right). Proteins in common between the two comparisons are highlighted in red. See also [Figures S6 and S7](#SD1){ref-type="supplementary-material"}.](nihms941209f7){#F7}

###### Highlights

-   Initiation of mutagenesis in the hemogenic endothelium yields hematopoietic malignancy

-   Pi4ka is expressed in hematopoietic stem progenitor cells

-   Pi4ka has a regulatory role in myelo- and erythropoiesis

-   PI4KAP2 is a protein-coding negative regulator of Pi4ka signaling

[^1]: Lead Contact
